Bladder Cancer Expert Debates Videos

Selecting the Appropriate Urinary Diversion Method for Bladder Cancer Patients - Bernard Bochner & Arnulf Stenzl

May 30, 2023

Details

Pros and Cons of Organ-Sparing Cystectomy in Bladder Cancer Patients: Balancing Oncologic and Functional Outcomes - Param Mariappan & Maria Carmen Mir

May 12, 2023

Details

Debating Treatment Options for Very High-Risk Non-Muscle-Invasive Bladder Cancer: BCG vs. Radical Cystectomy - Morgan Rouprêt & Laura Mertens

May 12, 2023

Details

Optimal TURBT: Do Skilled Urologists Really Need Photodynamic Diagnosis (PDD)? -Trinity Bivalacqua & Michael Cookson

May 2, 2023

Details

The Management of High-Grade T1 Bladder Cancer: Joan Palou and Alfred Witjes

January 4, 2023

Details

Highlighting 25 Years of the International Bladder Cancer Network (IBCN) - Barton Grossman

September 17, 2022

Details

Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf

December 16, 2021

Details

Choice of Urinary Diversion in Patients Undergoing Radical Cystectomy - Peter Black, Jens Bedke, and Hugh Mostafid

September 3, 2021

Details

Optimal Therapy for Patient with T0 After Neoadjuvant Chemotherapy - Sima Porten, Ananya Choudhury, Paolo Gontero, and Kamal Pohar

August 30, 2021

Details

A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg

June 7, 2021

Details

Evaluating Nadofaragene Firadenovec Phase III Clinical Trial Results as a New Gold Standard for BCG-Unresponsive Bladder Cancer - Trinity Bivalacqua & Nicholas James

January 25, 2021

Details

TURBT Quality Indicators and Access Issues in the United Kingdom - Param Mariappan & Prashant Patel

September 13, 2020

Details

Molecular Subtyping of Bladder Cancer: Ready for Prime Time? - Eva Comperat & Hikmat Al-Ahmadie

September 8, 2020

Details

T2 Muscle-Invasive Bladder Cancer: Tri-Modality Therapy (TMT) versus Radical Cystectomy - Stephen Williams & Nick James

July 2, 2020

Details

Neoadjuvant Immune-Checkpoint Inhibition Vs. Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Bladder Cancer (MIBC) - Andrea Necchi and Petros Grivas

June 29, 2020

Details

Management of High-Grade T1 Bladder Cancer: Cystectomy versus BCG - Bernard Bochner & Paolo Gontero

June 17, 2020

Details

Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin

June 15, 2020

Details

Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand & Trinity Bivalacqua

June 11, 2020

Details

A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black

June 8, 2020

Details